MASSACESI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.007
EU - Europa 16.647
AS - Asia 9.586
SA - Sud America 1.215
Continente sconosciuto - Info sul continente non disponibili 415
AF - Africa 313
OC - Oceania 174
Totale 49.357
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.606
RU - Federazione Russa 4.352
PL - Polonia 4.325
IT - Italia 3.587
SG - Singapore 2.525
CN - Cina 2.367
HK - Hong Kong 1.469
IE - Irlanda 982
VN - Vietnam 982
BR - Brasile 947
KR - Corea 801
SE - Svezia 738
DE - Germania 541
UA - Ucraina 461
FR - Francia 429
FI - Finlandia 426
IN - India 366
GB - Regno Unito 306
CA - Canada 246
JP - Giappone 195
BD - Bangladesh 190
AU - Australia 167
JO - Giordania 153
NL - Olanda 139
ID - Indonesia 113
CH - Svizzera 102
TR - Turchia 99
AR - Argentina 93
ES - Italia 82
MX - Messico 82
EC - Ecuador 58
CI - Costa d'Avorio 56
IQ - Iraq 50
MA - Marocco 50
ZA - Sudafrica 49
NG - Nigeria 48
SA - Arabia Saudita 40
CO - Colombia 36
PK - Pakistan 34
IR - Iran 33
PH - Filippine 28
BE - Belgio 24
EG - Egitto 24
AT - Austria 22
SC - Seychelles 22
VE - Venezuela 21
CL - Cile 17
LT - Lituania 17
UZ - Uzbekistan 17
KE - Kenya 15
PT - Portogallo 15
NP - Nepal 14
RO - Romania 14
TH - Thailandia 14
BJ - Benin 13
PY - Paraguay 13
CZ - Repubblica Ceca 12
MY - Malesia 12
PE - Perù 12
AZ - Azerbaigian 11
HN - Honduras 11
UY - Uruguay 11
DK - Danimarca 10
JM - Giamaica 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
CR - Costa Rica 9
IL - Israele 8
NO - Norvegia 8
DZ - Algeria 7
GR - Grecia 7
LV - Lettonia 7
NZ - Nuova Zelanda 7
TT - Trinidad e Tobago 7
AL - Albania 6
BH - Bahrain 6
BO - Bolivia 6
ET - Etiopia 6
KZ - Kazakistan 6
PR - Porto Rico 6
TW - Taiwan 6
DO - Repubblica Dominicana 5
GT - Guatemala 5
KW - Kuwait 5
PA - Panama 5
BG - Bulgaria 4
KG - Kirghizistan 4
MK - Macedonia 4
MM - Myanmar 4
NI - Nicaragua 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
XK - ???statistics.table.value.countryCode.XK??? 4
HR - Croazia 3
HU - Ungheria 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LK - Sri Lanka 3
LU - Lussemburgo 3
MQ - Martinica 3
Totale 48.898
Salva come PNG Salva come JPEG
Città #
Warsaw 4.309
Santa Clara 4.152
Ashburn 2.320
Singapore 1.796
Fairfield 1.384
Hong Kong 1.273
Dublin 976
San Jose 887
Chandler 870
Seoul 792
Milan 710
Woodbridge 645
Jacksonville 591
Seattle 578
Hefei 530
Houston 525
Cambridge 512
Beijing 497
Council Bluffs 458
Wilmington 449
Los Angeles 352
Altamura 343
Lawrence 340
Florence 339
Ho Chi Minh City 310
Rome 302
Buffalo 301
Princeton 262
Ann Arbor 256
Lauterbourg 249
Dallas 232
Boston 229
Hanoi 219
The Dalles 211
Mumbai 202
Helsinki 182
New York 182
Tokyo 179
Kent 162
Moscow 148
Munich 144
Boardman 142
Melbourne 135
Phoenix 118
Shanghai 101
Clifton 100
San Diego 92
Bern 89
São Paulo 89
Dearborn 88
Medford 88
Orem 81
Turku 78
Jakarta 72
Paris 70
Toronto 70
Naples 69
Turin 69
Chicago 66
Dong Ket 63
Bologna 58
Abidjan 56
Falls Church 56
Frankfurt am Main 54
Figino 50
Norwalk 49
Abuja 47
Chennai 46
Columbus 45
London 45
Brooklyn 43
Palermo 43
West Jordan 43
Da Nang 42
Redondo Beach 42
Barcelona 39
Montreal 38
Casablanca 37
Atlanta 35
Lappeenranta 35
Guangzhou 34
Denver 33
Miano 33
Bengaluru 31
Genoa 31
Manchester 31
Amsterdam 30
Belo Horizonte 30
Haiphong 30
Tianjin 30
Verona 30
Yubileyny 30
Catania 29
Rio de Janeiro 29
Hillsboro 28
Johannesburg 28
Frankfurt Am Main 27
Stockholm 27
Riyadh 26
Auburn Hills 25
Totale 32.573
Salva come PNG Salva come JPEG
Nome #
K index improves MS diagnosis and supports the differential diagnosis between MS and MS-like syndromes. 474
Proposal for a New Score-Based Approach To Improve Efficiency of Diagnostic Laboratory Workflow for Acute Bacterial Meningitis in Adults 463
Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop 398
A synthetic glycopeptide of human myelin oligodendrocyte glycoprotein to detect antibody responses in multiple sclerosis and other neurological diseases. 360
SWI enhances vein detection using gadolinium in multiple sclerosis. 359
Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. 339
A linkage analysis of Multiple Sclerosis with candidate region markers in Sardinian and Continental Italian families. 337
The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. 335
Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial. 332
Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT 331
Central vein sign differentiates MS from CNS inflammatory vasculopathies. 325
Magnetic resonance imaging of experimental autoimmune encephalomyelitis in the common marmoset. 321
Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: a new model for multiple sclerosis. 317
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. 312
Lysosomal enzymes in experimental allergic encephalomyelitis: time course and evidence of the source. 311
Azathioprine versus Beta Interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. 311
A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study 311
The Italian multiple sclerosis register. 307
No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. 306
Fetal striatal grafting slows motor and cognitive decline of Huntington's disease 306
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. 304
Survey of the italian neurological output in the three years 1989-1991. 292
Placebo-controlled multicentre randomised trial of Interferon beta-1b in treatment of secondary progressive multiple sclerosis. 292
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. 292
Histopathological characterization of magnetic resonance imaging-decectable brain white matter lesions in a primate model of multiple sclerosis. 286
Experimental allergic encephalomyelitis in Cynomolgus Monkeys: quantitation of T-cell responses in peripheral blood. 286
Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). 279
Effect of Interferon-β1b on Magnetic Resonance Imaging Outcomes in Secondary Progressive Multiple Sclerosis: Results of a European Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. 276
In healthy primates, circulating autoreactive T-cells mediate autoimmune disease. 276
Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial 274
Immunosuppressive activity of 13-cis retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats. 260
Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study 258
Carbon nanotube scaffolds instruct human dendritic cells: modulating immune responses by contacts at the nanoscale. 257
The formation of inflammatory demyelinated lesions in cerebral white matter. 257
Cyclophosphamide Pulse Therapy after Natalizumab Discontinuation for Multiple Sclerosis: a multicenter study. 257
Operationalizing mild cognitive impairment criteria in small vessel disease: The VMCI-Tuscany Study 256
Trapianto intracerebrale di striato fetale nella malattia di Huntington: un aggiornamento dell'esperienza clinica italiana 255
Amyloid Angiopathy related inflammation and paroxysmal events refractory to anti-seizure therapy: amyloid spells or seizures? 250
The “central vein sign” in patients with diagnostic “red flags” for multiple sclerosis: A prospective multicenter 3T study 246
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 245
Seizure recurrence risk after discontinuation of anti-seizure medications: prognostic factors and development of a new predictive scale 239
Subgroup Comparison According to Clinical Phenotype and Serostatus in Autoimmune Encephalitis: A Multicenter Retrospective Study 239
A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. 237
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. 233
HIGH RESOLUTION IMAGING TECHNIQUES OF THE RETINA AND OPTIC NERVE FOR THE ANALYSIS OF MICROSTRUCTURAL AND VASCULAR CHANGES IN MULTIPLE SCLEROSIS 231
Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: a phase II trial. 228
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies 228
MRI analysis of the "central vein sign" allows identification of a subset of relapsing remitting MS patients with brain pathology different from inflammatory demyelination 223
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis 220
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study 213
Evaluation of cognitive and language side effects of topiramate in patients with epilepsy, and effectiveness of counseling and speech therapy interventions 209
[Asn31(N-beta-D-Glucopyranosyl)]hMOG(30-50): an antigen to identify anti-hMOG peptide antibodies in multiple sclerosis patients. 206
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis 205
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation 205
A sequence variation in the MOG gene is involved in Multiple Sclerosis susceptibility in Italy. 203
Autologous Stem Cell Transplantation International Multiple Sclerosis (ASTIMS) trial: a randomised, phase II, controlled, multicentre trial 203
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: The Italian multi-centre experience 203
Predictors of response to opicinumab in acute optic neuritis 202
Decrypting the Spectrum of Antigen-Specific T-Cell Responses: The Avidity Repertoire of MBP-Specific T-Cells. 202
Perivenular brain lesions in a primate multiple sclerosis model at 7-tesla magnetic resonance imaging. 201
Accuracy of the central vein sign evaluation by brain MRI for the pathologic characterization of multiple sclerosis cases with markers of "better explanation" of the diagnosis. 201
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 198
Integrating novel neuroimaging measurements and circulating biomarkers for the prediction of secondary injury following stroke. the NIMBLE study. 198
Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation 198
SYNTHESIS OF LIPOPEPTIDES OF THE IMMUNODOMINANT EPITOPE HMBP(83-99) CONTAINING AMIDE OR C-C BOND LINKED HYDROPHOBIC CHAINS FOR THE STUDY OF T CELL RESPONSE 197
A genome screen for multiple sclerosis in Italian families. 196
Antibodies specific for the lipid-bound form of myelin basic protein during experimental autoimmune encephalomyelitis. 196
Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs 196
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 195
Effect of disease-modifying treatments on antibody-mediated response to anti- COVID19 vaccination in people with multiple sclerosis 195
Clinical and paraclinical findings in a case series of MOGAD: Exploring the presence of perivenular brain white matter lesions 193
Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). 193
Lipoderivatives of an immunodominant epitope of myelin basic protein increased T cell responsiveness in Lewis rats. 193
Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid bound form. 192
EFFECT OF LIPOCONJUGATION ON MBP PEPTIDE EPITOPES FOR CD4+ T CELL RESPONSIVENESS 191
Protein tyrosine phosphatase receptor-type C exon 4 gene mutation distribution in an Italian multiple sclerosis population. 190
Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy. 190
T-cell autoimmunity in multiple sclerosis. 189
Efficacy of Azathioprine on Multiple Sclerosis new brain lesions evaluated using Magnetic Resonance Imaging. 189
New approaches to the study of T-cell autoimmunity in multiple sclerosis. 187
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. 187
A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. 186
Immunosuppressive activity of 13-cis-retinoic acid in rats: aspects of pharmacokinetics and pharmacodynamics. 185
Neuropsychological assessment in aggressive multiple sclerosis treated with stem cell transplantation 184
Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report 184
Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. 183
Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. 182
MRI evaluation of the "central vein sign" in brain white matter lesions of multiple sclerosis and systemic autoimmune diseases. 182
Susceptibility weighted MRI can help differentiating pathogenesis of white matter lesions in MS and CNS inflammatory vasculopathies. 180
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. 180
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis 179
Short-term evolution of autoreactive T-cell repertoire in multiple sclerosis. 178
The diagnosis of multiple sclerosis with markers of "better explanation": accuracy of the "central vein sign" in uncovering pathogenic mechansms different from inflammatory demyelination 178
Headache and cerebrospinal fluid dynamics: spontaneous CSF rhinorrhea in a patient with history of idiopathic intracranial hypertension. 177
Short-term dynamics of circulating T cell receptor V beta repertoire in relapsing-remitting MS. 177
Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment 177
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 176
Acute unilateral sixth cranial nerve palsy and headache as initial manifestations of carcinomatous meningitis. 176
Differentiation by MRI between multiple sclerosis and MS-like syndromes with markers of "better explanation" of the diagnosis. 176
Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. 175
Totale 24.062
Salva come PNG Salva come JPEG
Categoria #
all - tutte 134.682
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 134.682
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.411 0 0 79 117 57 67 65 134 78 70 281 463
2022/20234.386 376 853 221 231 335 769 584 240 489 20 135 133
2023/20241.923 75 236 268 114 161 180 75 352 48 134 178 102
2024/202512.606 518 1.259 798 1.855 3.317 1.812 265 927 542 266 473 574
2025/202615.502 1.613 1.980 1.436 1.502 1.625 556 1.566 696 1.004 926 549 2.049
2026/20271.898 611 536 751 0 0 0 0 0 0 0 0 0
Totale 49.357